At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 72 enrolled
Drug / intervention
Vivitroldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
CURE Addiction Center of Excellence: Brain Mechanisms of Relapse and Recovery - Prescription Opiates/Medication
In Brief
A Phase 2 clinical trial evaluating Vivitrol for Prescription Opiate/Medication Dependence. Completed, enrolled 72 participants across 1 site.
Detailed Summary
The proposed project will use fMRI and specific probes of reward and inhibition as biomarkers predicting drug use during and after treatment in 72 subjects addicted to prescription opioids/medications. Subjects will be scanned before, during, and after 12 weeks of active medication. The brain fMRI measures will be correlated with the primary clinical outcome of drug use (by urine drug screen) during the treatment and follow-up phase.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2012
First PostedApr 2012
Primary CompletionJan 2021
TodayJul 2026
First PostedApr 30, 2012
Enrollment StartJan 1, 2012
Primary CompletionJan 1, 2021
TodayJul 2, 2026
Enrollment to primary: 9 yearsPosted 14.2 years ago
Interventions
Vivitroldrug
There are monthly injections of depot naltrexone for 3 months.